dornase alfa, 2.5 mg per ampule (overall ingredient)
overall: 4 1/2 in x 4 3/4 in x 2 1/2 in; 11.43 cm x 12.065 cm x 6.35 cm
foil packet: 1/2 in x 4 1/4 in; 1.27 cm x 10.795 cm
overall: 4 1/2 in x 4 3/4 in x 2 5/8 in; 11.43 cm x 12.065 cm x 6.6675 cm
United States: California, South San Francisco
Product expiration date:
(From insert) Daily administration of Pulmozyme Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function. In patients with an FVC of greater than or equal to 40% of predicited, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requireing parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.